14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
CSTM vs BTSG: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Constellium SE Class A (CSTM) captures the overall head-to-head institutional edge over BrightSpring Health Services, Inc. (BTSG) on higher Unified Composite conviction (64.9/100 BUY vs. 47.2/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while BTSG wins 4–2 across the 6-pillar growth and valuation breakdown. CSTM trades at $20.93 (8.1x Forward P/E, 8.6% operating margin) versus BTSG at $64.02 (26.5x Forward P/E, 3.5% operating margin).
Growth vs. Quality Trade-Off: CSTM earns the overall head-to-head edge with a stronger Unified Composite Score (64.9/100 BUY vs. BTSG 47.2/100 HOLD) and 1.89β · 48% Vol risk profile, whereas BTSG leads top-line expansion (+26.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CSTM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.2); meanwhile BTSG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Health Information Services value chain with $13.6B market capitalization and 3.5% operating margin.
OpEx & R&D Reinvestment9.0% of Rev ($939M)
90D Engineering Disclosures0 Published
Investor FAQ CSTM vs BTSG Key Questions & Quantitative Answers
As of Nov 19, 2026, Constellium SE Class A (CSTM) captures the overall head-to-head institutional edge over BrightSpring Health Services, Inc. (BTSG) on higher Unified Composite conviction (64.9/100 BUY vs. 47.2/100 HOLD) after splitting the core matrix 7–3 (led by Valuation Multiples, Profitability & Quality), while BTSG wins 4–2 across the 6-pillar growth and valuation breakdown. CSTM trades at $20.93 (8.1x Forward P/E, 8.6% operating margin) versus BTSG at $64.02 (26.5x Forward P/E, 3.5% operating margin). Growth vs. Quality Trade-Off: CSTM earns the overall head-to-head edge with a stronger Unified Composite Score (64.9/100 BUY vs. BTSG 47.2/100 HOLD) and 1.89β · 48% Vol risk profile, whereas BTSG leads top-line expansion (+26.4% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CSTM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.2); meanwhile BTSG trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 44.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BTSG leads the Growth & Scale pillar: CSTM posts +21.8% YoY revenue growth and +35.5% YoY earnings growth on $10.0B TTM revenue (16.3% gross margin, 8.6% operating margin), compared with BTSG at +26.4% YoY revenue growth and +82.0% YoY earnings growth on $10.4B TTM revenue (12.5% gross margin, 3.5% operating margin). Across the 4-period historical trajectory (FY2022 to FY2025), CSTM cumulative revenue shifted -0.9% while BTSG shifted +67.2%. In operating R&D and SG&A reinvestment, CSTM deploys 7.7% of Rev ($774M) (0 90-day corporate R&D disclosures) versus 9.0% of Rev ($939M) (0 disclosures) for BTSG.
CSTM screens cheaper on headline valuation multiples. CSTM trades at 8.1x Forward P/E, 5.2x Trailing P/E, 0.40x PEG, and 0.5x EV/Revenue (3.2% FCF margin), whereas BTSG trades at 26.5x Forward P/E, 48.5x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (3.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CSTM (52.3% ROE) versus BTSG (15.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CSTM carries 45.8% implied volatility (21st %ile, Compressed (<25th %ile)), a 3.16x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 48% Vol realized risk). By comparison, BTSG carries 44.4% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 2.01x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.93β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.